Biologic adjuvants for fracture healing

Arthritis Research and Therapy

Volumn 14, Issue 5, 2012, Pages

  Virk, Mandeep S ^a   Lieberman, Jay R ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANABOLIC AGENT; BIOLOGICAL PRODUCT; CALCIUM; CALCIUM PHOSPHATE; COLECALCIFEROL; COLLAGEN SPONGE; DICKKOPF 1 PROTEIN; FIBROBLAST GROWTH FACTOR 10; PARATHYROID HORMONE; PARATHYROID HORMONE[1-34]; PLACEBO; PLATELET DERIVED GROWTH FACTOR AA; PLATELET DERIVED GROWTH FACTOR BB; RECOMBINANT BONE MORPHOGENETIC PROTEIN 2; RECOMBINANT FIBROBLAST GROWTH FACTOR; RECOMBINANT OSTEOGENIC PROTEIN 1; RECOMBINANT PARATHYROID HORMONE; RECOMBINANT PLATELET DERIVED GROWTH FACTOR; RECOMBINANT PLATELET DERIVED GROWTH FACTOR BB; REPIFERMIN; SCLEROSTIN; BONE MORPHOGENETIC PROTEIN;

ANKLE ARTHRODESIS; BIOLOGICAL ACTIVITY; BIOLOGICAL THERAPY; BONE DEFECT; BONE DEVELOPMENT; BONE GRAFT; BONE MARROW BIOPSY; BONE MARROW TRANSPLANTATION; BONE MATRIX; BONE REMODELING; BONE TISSUE; CALLUS; CELL AGING; CELL CULTURE; CELL EXPANSION; CELL RENEWAL; CELL THERAPY; CLINICAL TRIAL (TOPIC); COLONY FORMING UNIT F; DISTAL TIBIA FRACTURE; DRUG EFFICACY; DRUG INTERMITTENT THERAPY; DYSPHAGIA; EXTERNAL FIXATOR; FEMUR FRACTURE; FIBULA FRACTURE; FIBULA OSTEOTOMY; FRACTURE HEALING; FRACTURE NONUNION; GENE THERAPY; HETEROTOPIC OSSIFICATION; HUMAN; INFECTION; INTRAMEDULLARY NAIL; MESENCHYMAL STEM CELL; MULTICENTER STUDY (TOPIC); NONHUMAN; OFF LABEL DRUG USE; OPEN FRACTURE; ORTHOPEDIC EQUIPMENT; OSTEOBLAST; OSTEOPENIA; OSTEOPOROSIS; PARAPLEGIA; PELVIS FRACTURE; PERIODONTAL DISEASE; PLURIPOTENT STEM CELL; RADIUS FRACTURE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SCAPHOID FRACTURE; STEM CELL; TIBIA FRACTURE; TIBIA OSTEOTOMY; TIBIA SHAFT FRACTURE; TISSUE INJURY; TISSUE REGENERATION; TISSUE REPAIR; ULNA FRACTURE; BONE REGENERATION; FRACTURES, BONE; PATHOPHYSIOLOGY; PROCEDURES; TREATMENT OUTCOME;

BIOLOGICAL PRODUCTS; BONE MORPHOGENETIC PROTEINS; BONE REGENERATION; CELL- AND TISSUE-BASED THERAPY; FRACTURE HEALING; FRACTURES, BONE; HUMANS; OSTEOGENESIS; PARATHYROID HORMONE; TREATMENT OUTCOME;

EID: 84870391273     PISSN: 14786354     EISSN: 14786362     Source Type: Journal    
DOI: 10.1186/ar4053     Document Type: Review

References (90)

1. Axelrad TW, Kakar S, Einhorn TA. New technologies for the enhancement of skeletal repair. Injury 2007, 38(Suppl 1):S49-62.
2. Heckman JD, Sarasohn-Kahn J. The economics of treating tibia fractures. The cost of delayed unions. Bull Hosp Jt Dis 1997, 56:63-72.
3. Lieberman JR. Orthopaedic gene therapy. Fracture healing and other nongenetic problems of bone. Clin Orthop Relat Res 2000, (379 Suppl):S156-158.
4. Carofino BC, Lieberman JR. Gene therapy applications for fracture-healing. J Bone Joint Surg Am 2008, 90(Suppl 1):99-110.
5. Patterson TE, Kumagai K, Griffith L, Muschler GF. Cellular strategies for enhancement of fracture repair. J Bone Joint Surg Am 2008, 90(Suppl 1):111-119.
6. Muschler GF, Midura RJ. Connective tissue progenitors: practical concepts for clinical applications. Clin Orthop Relat Res 2002, (395):66-80.
7. Khosla S, Westendorf JJ, Modder UI. Concise review: Insights from normal bone remodeling and stem cell-based therapies for bone repair. Stem Cells 2010, 28:2124-2128. 10.1002/stem.546, 3125598, 20960512.
8. Giordano A, Galderisi U, Marino IR. From the laboratory bench to the patient's bedside: an update on clinical trials with mesenchymal stem cells. J Cell Physiol 2007, 211:27-35. 10.1002/jcp.20959, 17226788.
9. Friedenstein AJ, Petrakova KV, Kurolesova AI, Frolova GP. Heterotopic of bone marrow. Analysis of precursor cells for osteogenic and hematopoietic tissues. Transplantation 1968, 6:230-247. 10.1097/00007890-196803000-00009, 5654088.
10. Bajada S, Harrison PE, Ashton BA, Cassar-Pullicino VN, Ashammakhi N, Richardson JB. Successful treatment of refractory tibial nonunion using calcium sulphate and bone marrow stromal cell implantation. J Bone Joint Surg Br 2007, 89:1382-1386. 10.1302/0301-620X.89B10.19103, 17957083.
11. Marcacci M, Kon E, Moukhachev V, Lavroukov A, Kutepov S, Quarto R, Mastrogiacomo M, Cancedda R. Stem cells associated with macroporous bioceramics for long bone repair: 6- to 7-year outcome of a pilot clinical study. Tissue Eng 2007, 13:947-955. 10.1089/ten.2006.0271, 17484701.
12. Quarto R, Mastrogiacomo M, Cancedda R, Kutepov SM, Mukhachev V, Lavroukov A, Kon E, Marcacci M. Repair of large bone defects with the use of autologous bone marrow stromal cells. N Engl J Med 2001, 344:385-386. 10.1056/NEJM200102013440516, 11195802.
13. Kim SJ, Shin YW, Yang KH, Kim SB, Yoo MJ, Han SK, Im SA, Won YD, Sung YB, Jeon TS, Chang CH, Jang JD, Lee SB, Kim HC, Lee SY. A multi-center, randomized, clinical study to compare the effect and safety of autologous cultured osteoblast (Ossron) injection to treat fractures. BMC Musculoskelet Disord 2009, 10:20. 10.1186/1471-2474-10-20, 2656455, 19216734.
14. Tseng SS, Lee MA, Reddi AH. Nonunions and the potential of stem cells in fracture-healing. J Bone Joint Surg Am 2008, 90(Suppl 1):92-98.
15. Goel A, Sangwan SS, Siwach RC, Ali AM. Percutaneous bone marrow grafting for the treatment of tibial non-union. Injury 2005, 36:203-206. 10.1016/j.injury.2004.01.009, 15589942.
16. Hernigou P, Mathieu G, Poignard A, Manicom O, Beaujean F, Rouard H. Percutaneous autologous bone-marrow grafting for nonunions. Surgical technique. J Bone Joint Surg Am 2006, 88(Suppl 1 Pt 2):322-327.
17. Galois L, Bensoussan D, Diligent J, Pinzano A, Henrionnet C, Choufani E, Stoltz JF, Mainard D. Autologous bone marrow graft and treatment of delayed and non-unions of long bones: technical aspects. Biomed Mater Eng 2009, 19:277-281.
18. Connolly JF, Guse R, Tiedeman J, Dehne R. Autologous marrow injection as a substitute for operative grafting of tibial nonunions. Clin Orthop Relat Res 1991, (266):259-270.
19. Connolly JF. Clinical use of marrow osteoprogenitor cells to stimulate osteogenesis. Clin Orthop Relat Res 1998, (355 Suppl):S257-266.
20. Bhargava R, Sankhla S, Gupta A, Changani R, Gagal K. Percutaneous autologus bone marrow injection in the treatment of delayed or nonunion. Indian J Orthop 2007, 41:67-71. 10.4103/0019-5413.30529, 2981899, 21124686.
21. Sim R, Liang TS, Tay BK. Autologous marrow injection in the treatment of delayed and non-union in long bones. Singapore Med J 1993, 34:412-417.
22. Garg NK, Gaur S, Sharma S. Percutaneous autogenous bone marrow grafting in 20 cases of ununited fracture. Acta Orthop Scand 1993, 64:671-672. 10.3109/17453679308994595, 8291415.
23. Kettunen J, Makela EA, Turunen V, Suomalainen O, Partanen K. Percutaneous bone grafting in the treatment of the delayed union and non-union of tibial fractures. Injury 2002, 33:239-245. 10.1016/S0020-1383(01)00075-4, 12084640.
24. Khanal GP, Garg M, Singh GK. A prospective randomized trial of percutaneous marrow injection in a series of closed fresh tibial fractures. Int Orthop 2004, 28:167-170. 10.1007/s00264-004-0547-0, 3474489, 15007562.
25. Hernigou P, Poignard A, Beaujean F, Rouard H. Percutaneous autologous bone-marrow grafting for nonunions. Influence of the number and concentration of progenitor cells. J Bone Joint Surg Am 2005, 87:1430-1437. 10.2106/JBJS.D.02215, 15995108.
26. Cuomo AV, Virk M, Petrigliano F, Morgan EF, Lieberman JR. Mesenchymal stem cell concentration and bone repair: potential pitfalls from bench to bedside. J Bone Joint Surg Am 2009, 91:1073-1083. 10.2106/JBJS.H.00303, 19411455.
27. Muschler GF, Boehm C, Easley K. Aspiration to obtain osteoblast progenitor cells from human bone marrow: the influence of aspiration volume. J Bone Joint Surg Am 1997, 79:1699-1709.
28. Seebach C, Henrich D, Tewksbury R, Wilhelm K, Marzi I. Number and proliferative capacity of human mesenchymal stem cells are modulated positively in multiple trauma patients and negatively in atrophic nonunions. Calcif Tissue Int 2007, 80:294-300. 10.1007/s00223-007-9020-6, 17431529.
29. Wilkins RM, Chimenti BT, Rifkin RM. Percutaneous treatment of long bone nonunions: the use of autologous bone marrow and allograft bone matrix. Orthopedics 2003, 26(5 Suppl):s549-554.
30. Sakai S, Mishima H, Ishii T, Akaogi H, Yoshioka T, Uemura T, Ochiai N. Concentration of bone marrow aspirate for osteogenic repair using simple centrifugal methods. Acta Orthop 2008, 79:445-448. 10.1080/17453670710015382, 18626810.
31. Chen D, Zhao M, Mundy GR. Bone morphogenetic proteins. Growth Factors 2004, 22:233-241. 10.1080/08977190412331279890, 15621726.
32. Lieberman JR, Daluiski A, Einhorn TA. The role of growth factors in the repair of bone. Biology and clinical applications. J Bone Joint Surg Am 2002, 84-A:1032-1044.
33. Urist MR. Bone: formation by autoinduction. Science 1965, 150:893-899. 10.1126/science.150.3698.893, 5319761.
34. Bragdon B, Moseychuk O, Saldanha S, King D, Julian J, Nohe A. Bone morphogenetic proteins: a critical review. Cell Signal 2011, 23:609-620. 10.1016/j.cellsig.2010.10.003, 20959140.
35. Canalis E, Economides AN, Gazzerro E. Bone morphogenetic proteins, their antagonists, and the skeleton. Endocr Rev 2003, 24:218-235. 10.1210/er.2002-0023, 12700180.
36. Govender S, Csimma C, Genant HK, Valentin-Opran A, Amit Y, Arbel R, Aro H, Atar D, Bishay M, Börner MG, Chiron P, Choong P, Cinats J, Courtenay B, Feibel R, Geulette B, Gravel C, Haas N, Raschke M, Hammacher E, van der Velde D, Hardy P, Holt M, Josten C, Ketterl RL, Lindeque B, Lob G, Mathevon H, McCoy G, Marsh D, et al. Recombinant human bone morphogenetic protein-2 for treatment of open tibial fractures: a prospective, controlled, randomized study of four hundred and fifty patients. J Bone Joint Surg Am 2002, 84-A:2123-2134.
37. Jones AL, Bucholz RW, Bosse MJ, Mirza SK, Lyon TR, Webb LX, Pollak AN, Golden JD, Valentin-Opran A. Recombinant human BMP-2 and allograft compared with autogenous bone graft for reconstruction of diaphyseal tibial fractures with cortical defects. A randomized, controlled trial. J Bone Joint Surg Am 2006, 88:1431-1441. 10.2106/JBJS.E.00381, 16818967.
38. Aro HT, Govender S, Patel AD, Hernigou P, Perera de Gregorio A, Popescu GI, Golden JD, Christensen J, Valentin A. Recombinant human bone morphogenetic protein-2: a randomized trial in open tibial fractures treated with reamed nail fixation. J Bone Joint Surg Am 2011, 93:801-808.
39. Friedlaender GE, Perry CR, Cole JD, Cook SD, Cierny G, Muschler GF, Zych GA, Calhoun JH, LaForte AJ, Yin S. Osteogenic protein-1 (bone morphogenetic protein-7) in the treatment of tibial nonunions. J Bone Joint Surg Am 2001, 83-A(Suppl 1 (Pt 2)):S151-158. 1425155, 11314793.
40. Ekrol I, Hajducka C, Court-Brown C, McQueen MM. A comparison of RhBMP-7 (OP-1) and autogenous graft for metaphyseal defects after osteotomy of the distal radius. Injury 2008, 39(Suppl 2):S73-82.
41. Lieberman JR, Daluiski A, Stevenson S, Wu L, McAllister P, Lee YP, Kabo JM, Finerman GA, Berk AJ, Witte ON. The effect of regional gene therapy with bone morphogenetic protein-2-producing bone-marrow cells on the repair of segmental femoral defects in rats. J Bone Joint Surg Am 1999, 81:905-917.
42. Seeherman HJ, Li XJ, Bouxsein ML, Wozney JM. rhBMP-2 induces transient bone resorption followed by bone formation in a nonhuman primate core-defect model. J Bone Joint Surg Am 2010, 92:411-426. 10.2106/JBJS.H.01732, 20124069.
43. Carragee EJ, Hurwitz EL, Weiner BK. A critical review of recombinant human bone morphogenetic protein-2 trials in spinal surgery: emerging safety concerns and lessons learned. Spine J 2011, 11:471-491. 10.1016/j.spinee.2011.04.023, 21729796.
44. Shields LB, Raque GH, Glassman SD, Campbell M, Vitaz T, Harpring J, Shields CB. Adverse effects associated with high-dose recombinant human bone morphogenetic protein-2 use in anterior cervical spine fusion. Spine (Phila Pa 1976) 2006, 31:542-547.
45. Vaidya R, Carp J, Sethi A, Bartol S, Craig J, Les CM. Complications of anterior cervical discectomy and fusion using recombinant human bone morphogenetic protein-2. Eur Spine J 2007, 16:1257-1265. 10.1007/s00586-007-0351-9, 2200768, 17387522.
46. Garrison KR, Shemilt I, Donell S, Ryder JJ, Mugford M, Harvey I, Song F, Alt V. Bone morphogenetic protein (BMP) for fracture healing in adults. Cochrane Database Syst Rev (6):CD006950.
47. Beenken A, Mohammadi M. The FGF family: biology, pathophysiology and therapy. Nat Rev Drug Discov 2009, 8:235-253. 10.1038/nrd2792, 19247306.
48. Marie PJ. Fibroblast growth factor signaling controlling osteoblast differentiation. Gene 2003, 316:23-32.
49. Kawaguchi H. [Bone fracture and the healing mechanisms. Fibroblast growth factor-2 and fracture healing]. Clin Calcium 2009, 19:653-659. In Japanese.
50. Kawaguchi H, Oka H, Jingushi S, Izumi T, Fukunaga M, Sato K, Matsushita T, Nakamura K. A local application of recombinant human fibroblast growth factor 2 for tibial shaft fractures: a randomized, placebo-controlled trial. J Bone Miner Res 2010, 25:2735-2743. 10.1002/jbmr.146, 20533373.
51. Kawaguchi H, Jingushi S, Izumi T, Fukunaga M, Matsushita T, Nakamura T, Mizuno K, Nakamura T, Nakamura K. Local application of recombinant human fibroblast growth factor-2 on bone repair: a dose-escalation prospective trial on patients with osteotomy. J Orthop Res 2007, 25:480-487. 10.1002/jor.20315, 17205557.
52. Hollinger JO, Hart CE, Hirsch SN, Lynch S, Friedlaender GE. Recombinant human platelet-derived growth factor: biology and clinical applications. J Bone Joint Surg Am 2008, 90(Suppl 1):48-54.
53. Andrae J, Gallini R, Betsholtz C. Role of platelet-derived growth factors in physiology and medicine. Genes Dev 2008, 22:1276-1312. 10.1101/gad.1653708, 2732412, 18483217.
54. DiGiovanni CW, Petricek JM. The evolution of rhPDGF-BB in musculoskeletal repair and its role in foot and ankle fusion surgery. Foot Ankle Clin 2010, 15:621-640. 10.1016/j.fcl.2010.07.001, 21056861.
55. Daniels T, DiGiovanni C, Lau JT, Wing K, Younger A. Prospective clinical pilot trial in a single cohort group of rhPDGF in foot arthrodeses. Foot Ankle Int 2010, 31:473-479. 10.3113/FAI.2010.0473, 20557811.
56. Digiovanni CW, Baumhauer J, Lin SS, Berberian WS, Flemister AS, Enna MJ, Evangelista P, Newman J. Prospective, randomized, multi-center feasibility trial of rhPDGF-BB versus autologous bone graft in a foot and ankle fusion model. Foot Ankle Int 2011, 32:344-354. 10.3113/FAI.2011.0344, 21733435.
57. Jilka RL. Molecular and cellular mechanisms of the anabolic effect of intermittent PTH. Bone 2007, 40:1434-1446. 10.1016/j.bone.2007.03.017, 1995599, 17517365.
58. Bukata SV, Puzas JE. Orthopedic uses of teriparatide. Curr Osteoporos Rep 2010, 8:28-33. 10.1007/s11914-010-0006-3, 20425088.
59. Rubin MR, Bilezikian JP. Parathyroid hormone as an anabolic skeletal therapy. Drugs 2005, 65:2481-2498. 10.2165/00003495-200565170-00005, 16296873.
60. Ellegaard M, Jørgensen NR, Schwarz P. Parathyroid hormone and bone healing. Calcif Tissue Int 2010, 87:1-13. 10.1007/s00223-010-9360-5, 20428858.
61. Aspenberg P, Johansson T. Teriparatide improves early callus formation in distal radial fractures. Acta Orthop 2010, 81:234-236. 10.3109/17453671003761946, 2895344, 20367417.
62. Peichl P, Holzer LA, Maier R, Holzer G. Parathyroid hormone 1-84 accelerates fracture-healing in pubic bones of elderly osteoporotic women. J Bone Joint Surg Am 2011, 93:1583-1587. 10.2106/JBJS.J.01379, 21915572.
63. Aspenberg P, Genant HK, Johansson T, Nino AJ, See K, Krohn K, García-Hernández PA, Recknor CP, Einhorn TA, Dalsky GP, Mitlak BH, Fierlinger A, Lakshmanan MC. Teriparatide for acceleration of fracture repair in humans: a prospective, randomized, double-blind study of 102 postmenopausal women with distal radial fractures. J Bone Miner Res 2010, 25:404-414. 10.1359/jbmr.090731, 19594305.
64. Chintamaneni S, Finzel K, Gruber BL. Successful treatment of sternal fracture nonunion with teriparatide. Osteoporos Int 2010, 21:1059-1063. 10.1007/s00198-009-1061-4, 19859645.
65. Rubery PT, Bukata SV. Teriparatide may accelerate healing in delayed unions of type III odontoid fractures: a report of 3 cases. J Spinal Disord Tech 2010, 23:151-155. 10.1097/BSD.0b013e31819a8b7a, 20051918.
66. Oteo-Alvaro A, Moreno E. Atrophic humeral shaft nonunion treated with teriparatide (rh PTH 1-34): a case report. J Shoulder Elbow Surg 2010, 19:e22-28.
67. Gazit D, Turgeman G, Kelley P, Wang E, Jalenak M, Zilberman Y, Moutsatsos I. Engineered pluripotent mesenchymal cells integrate and differentiate in regenerating bone: a novel cell-mediated gene therapy. J Gene Med 1999, 1:121-133. 10.1002/(SICI)1521-2254(199903/04)1:2<121::AID-JGM26>3.0.CO;2-J, 10738576.
68. Gamradt SC, Abe N, Bahamonde ME, Lee YP, Nelson SD, Lyons KM, Lieberman JR. Tracking expression of virally mediated BMP-2 in gene therapy for bone repair. Clin Orthop Relat Res 2006, 450:238-245.
69. Virk MS, Sugiyama O, Park SH, Gambhir SS, Adams DJ, Drissi H, Lieberman JR. 'Same day' ex-vivo regional gene therapy: a novel strategy to enhance bone repair. Mol Ther 2011, 19:960-968. 10.1038/mt.2011.2, 3098640, 21343916.
70. Evans CH, Ghivizzani SC, Robbins PD. The 2003 Nicolas Andry Award. Orthopaedic gene therapy. Clin Orthop Relat Res 2004, (429):316-329.
71. Betz OB, Betz VM, Nazarian A, Pilapil CG, Vrahas MS, Bouxsein ML, Gerstenfeld LC, Einhorn TA, Evans CH. Direct percutaneous gene delivery to enhance healing of segmental bone defects. J Bone Joint Surg Am 2006, 88:355-365. 10.2106/JBJS.E.00464, 16452748.
72. Yazici C, Takahata M, Reynolds DG, Xie C, Samulski RJ, Samulski J, Beecham EJ, Gertzman AA, Spilker M, Zhang X, O'Keefe RJ, Awad HA, Schwarz EM. Self-complementary AAV2.5-BMP2-coated femoral allografts mediated superior bone healing versus live autografts in mice with equivalent biomechanics to unfractured femur. Mol Ther 2011, 19:1416-1425. 10.1038/mt.2010.294, 3149158, 21206485.
73. Bukata SV. Systemic administration of pharmacological agents and bone repair: what can we expect. Injury 2011, 42:605-608. 10.1016/j.injury.2011.03.061, 21507402.
74. van Bezooijen RL, ten Dijke P, Papapoulos SE, Lowik CW. SOST/sclerostin, an osteocyte-derived negative regulator of bone formation. Cytokine Growth Factor Rev 2005, 16:319-327. 10.1016/j.cytogfr.2005.02.005, 15869900.
75. ten Dijke P, Krause C, de Gorter DJ, Lowik CW, van Bezooijen RL. Osteocytederived sclerostin inhibits bone formation: its role in bone morphogenetic protein and Wnt signaling. J Bone Joint Surg Am 2008, 90(Suppl 1):31-35.
76. Ominsky MS, Li C, Li X, Tan HL, Lee E, Barrero M, Asuncion FJ, Dwyer D, Han CY, Vlasseros F, Samadfam R, Jolette J, Smith SY, Stolina M, Lacey DL, Simonet WS, Paszty C, Li G, Ke HZ. Inhibition of sclerostin by monoclonal antibody enhances bone healing and improves bone density and strength of non-fractured bones. J Bone Miner Res 2011, 26:1012-1021. 10.1002/jbmr.307, 21542004.
77. Virk MS, Saquib SF, Farhang A, Lieberman JR. Influence of sclerostin antibody on bone repair in a rat femoral defect model. 55th Annual Orthopaedic Research Society Meeting 2009, Las Vegas, NV.
78. Daoussis D, Andonopoulos AP. The emerging role of dickkopf-1 in bone biology: is it the main switch controlling bone and joint remodeling?. Semin Arthritis Rheum 2011, 41:170-177. 10.1016/j.semarthrit.2011.01.006, 21435697.
79. Agholme F, Isaksson H, Kuhstoss S, Aspenberg P. The effects of Dickkopf-1 antibody on metaphyseal bone and implant fixation under different loading conditions. Bone 2011, 48:988-996. 10.1016/j.bone.2011.02.008, 21329773.
80. Vannabouathong C, Sprague S, Bhandari M. Guidelines for fracture healing assessments in clinical trials. Part I: definitions and endpoint committees. Injury 2011, 42:314-316. 10.1016/j.injury.2010.11.048, 21194691.
81. Morshed S, Bhandari M. Clinical trial design in fracture-healing research: meeting the challenge. J Bone Joint Surg Am 2008, 90(Suppl 1):55-61.
82. Morshed S, Corrales L, Genant H, Miclau T 3. Outcome assessment in clinical trials of fracture-healing. J Bone Joint Surg Am 2008, 90(Suppl 1):62-67.
83. Reynolds DG, Shaikh S, Papuga MO, Lerner AL, O''Keefe RJ, Schwarz EM, Awad HA. muCT-based measurement of cortical bone graft-to-host union. J Bone Miner Res 2009, 24:899-907. 10.1359/jbmr.081232, 2672207, 19063685.
84. Garrison KR, Donell S, Ryder J, Shemilt I, Mugford M, Harvey I, Song F. Clinical effectiveness and cost-effectiveness of bone morphogenetic proteins in the non-healing of fractures and spinal fusion: a systematic review. Health Technol Assess 2007, 11:1-150. iii-iv.
85. Swiontkowski MF, Aro HT, Donell S, Esterhai JL, Goulet J, Jones A, Kregor PJ, Nordsletten L, Paiement G, Patel A. Recombinant human bone morphogenetic protein-2 in open tibial fractures. A subgroup analysis of data combined from two prospective randomized studies. J Bone Joint Surg Am 2006, 88:1258-1265. 10.2106/JBJS.E.00499, 16757759.
86. Calori GM, Tagliabue L, Gala L, d'Imporzano M, Peretti G, Albisetti W. Application of rhBMP-7 and platelet-rich plasma in the treatment of long bone non-unions: a prospective randomised clinical study on 120 patients. Injury 2008, 39:1391-1402. 10.1016/j.injury.2008.08.011, 19027898.
87. Ristiniemi J, Flinkkila T, Hyvonen P, Lakovaara M, Pakarinen H, Jalovaara P. RhBMP-7 accelerates the healing in distal tibial fractures treated by external fixation. J Bone Joint Surg Br 2007, 89:265-272. 10.1302/0301-620X.89B2.18230, 17322450.
88. Bilic R, Simic P, Jelic M, Stern-Padovan R, Dodig D, van Meerdervoort HP, Martinovic S, Ivankovic D, Pecina M, Vukicevic S. Osteogenic protein-1 (BMP-7) accelerates healing of scaphoid non-union with proximal pole sclerosis. Int Orthop 2006, 30:128-134. 10.1007/s00264-005-0045-z, 2532081, 16506027.
89. McKee MD, Schemitsch EH, Waddell JP, Kreder HJ, Stephen DJG, Leighton RK, Buckley RE, Powell JN, Wild LM, Blachut PA, O''Brien PJ, Pirani S, McCormack TG, . the Canadian Orthopaedic Trauma Society St Michael's Hospital, University of Toronto, Toronto, Ontario, Canada (a-Stryker Biotech, Inc.) The effect of human recombinant bone morphogenic protein (RHBMP-7) on the healing of open tibial shaft fractures: results of a multi-center, prospective, randomized clinical trial. Proceedings of the 18th Annual Meeting of the Orthopaedic Trauma Association 2002, 2002:157-158. Toronto, ON, Canada, the Canadian Orthopaedic Trauma Society St Michael's Hospital, University of Toronto, Toronto, Ontario, Canada (a-Stryker Biotech, Inc.).
90. Geesink RG, Hoefnagels NH, Bulstra SK. Osteogenic activity of OP-1 bone morphogenetic protein (BMP-7) in a human fibular defect. J Bone Joint Surg Br 1999, 81:710-718. 10.1302/0301-620X.81B4.9311, 10463751.